
Adverum Biotechnologies Investor Relations Material
Latest events

Status Update
Adverum Biotechnologies
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Adverum Biotechnologies Inc
Access all reports
Adverum Biotechnologies Inc, originally known as Avalanche Biotechnologies Inc, is a clinical-stage gene therapy company based in Redwood City, California. Focused on addressing unmet medical needs, the company targets serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). It leverages its proprietary intravitreal (IVT) platform to develop durable, single-administration therapies intended to be delivered in physicians' offices. This approach aims to transform the standard of care for highly prevalent ocular diseases by eliminating the need for frequent ocular injections. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.
Key slides for Adverum Biotechnologies Inc


Status Update
Adverum Biotechnologies Inc


Status Update
Adverum Biotechnologies Inc
Latest articles
)
Upcoming IPOs to Watch in 2025
Potential IPOs in 2025 include prominent names like Shein, Databricks, Klarna, eToro, and Figma, to name a few. Let's take a closer look.
23 May 2025
)
Figma: Collaborative Design Tool Ready for IPO
Figma, the popular design platform, is preparing for a potential IPO in 2025 as it continues to reshape the future of collaborative design.
22 May 2025
)
Companies That Had Their IPO in 2024: Momentum Increasing
2024 marked a steady year for IPOs, driven by strong markets, AI momentum, and high-profile listings across industries and regions.
22 May 2025
Ticker symbol
ADVM
Country
🇺🇸 United States